H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| EMERGENT BIOSOLUTIONS, Inc. (NYSE: EBS) | Delayed: 6.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.34 | 52 Week High | $44.38 | |||
| Open | $6.34 | 52 Week Low | $24.47 | |||
| Day High | $6.34 | P/E | 317.00 | |||
| Day Low | $6.34 | EPS | $0.02 | |||
| Volume | 1 | |||||
